These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 16026650)

  • 21. A novel doxorubicin-glucuronide prodrug DOX-GA3 for tumour-selective chemotherapy: distribution and efficacy in experimental human ovarian cancer.
    Houba PH; Boven E; van der Meulen-Muileman IH; Leenders RG; Scheeren JW; Pinedo HM; Haisma HJ
    Br J Cancer; 2001 Feb; 84(4):550-7. PubMed ID: 11207053
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Surfactant-polymer nanoparticles: a novel platform for sustained and enhanced cellular delivery of water-soluble molecules.
    Chavanpatil MD; Khdair A; Panyam J
    Pharm Res; 2007 Apr; 24(4):803-10. PubMed ID: 17318416
    [TBL] [Abstract][Full Text] [Related]  

  • 23. N-hexanoyl-sphingomyelin potentiates in vitro doxorubicin cytotoxicity by enhancing its cellular influx.
    Veldman RJ; Zerp S; van Blitterswijk WJ; Verheij M
    Br J Cancer; 2004 Feb; 90(4):917-25. PubMed ID: 14970874
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhanced intracellular uptake of sterically stabilized liposomal Doxorubicin in vitro resulting in improved antitumor activity in vivo.
    Xiong XB; Huang Y; Lu WL; Zhang H; Zhang X; Zhang Q
    Pharm Res; 2005 Jun; 22(6):933-9. PubMed ID: 15948037
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pronounced Cellular Uptake of Pirarubicin versus That of Other Anthracyclines: Comparison of HPMA Copolymer Conjugates of Pirarubicin and Doxorubicin.
    Nakamura H; Koziolová E; Chytil P; Tsukigawa K; Fang J; Haratake M; Ulbrich K; Etrych T; Maeda H
    Mol Pharm; 2016 Dec; 13(12):4106-4115. PubMed ID: 27934482
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro cytotoxic study of immunoliposomal doxorubicin targeted to human CD34(+) leukemic cells.
    Carrion C; de Madariaga MA; Domingo JC
    Life Sci; 2004 Jun; 75(3):313-28. PubMed ID: 15135652
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Coformulated N-octanoyl-glucosylceramide improves cellular delivery and cytotoxicity of liposomal doxorubicin.
    Veldman RJ; Koning GA; van Hell A; Zerp S; Vink SR; Storm G; Verheij M; van Blitterswijk WJ
    J Pharmacol Exp Ther; 2005 Nov; 315(2):704-10. PubMed ID: 16040815
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer.
    Charrois GJ; Allen TM
    Biochim Biophys Acta; 2004 May; 1663(1-2):167-77. PubMed ID: 15157619
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of active and passive targeting of doxorubicin for somatostatin receptor 2 positive tumor models by octreotide-modified HPMA copolymer-doxorubicin conjugates.
    He S; Zhou Z; Li L; Yang Q; Yang Y; Guan S; Zhang J; Zhu X; Jin Y; Huang Y
    Drug Deliv; 2016; 23(1):285-96. PubMed ID: 24865288
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy?
    Cui J; Li C; Guo W; Li Y; Wang C; Zhang L; Zhang L; Hao Y; Wang Y
    J Control Release; 2007 Apr; 118(2):204-15. PubMed ID: 17239468
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enriching lipid nanovesicles with short-chain glucosylceramide improves doxorubicin delivery and efficacy in solid tumors.
    van Lummel M; van Blitterswijk WJ; Vink SR; Veldman RJ; van der Valk MA; Schipper D; Dicheva BM; Eggermont AM; ten Hagen TL; Verheij M; Koning GA
    FASEB J; 2011 Jan; 25(1):280-9. PubMed ID: 20876209
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transferrin as a drug carrier: Cytotoxicity, cellular uptake and transport kinetics of doxorubicin transferrin conjugate in the human leukemia cells.
    Szwed M; Matusiak A; Laroche-Clary A; Robert J; Marszalek I; Jozwiak Z
    Toxicol In Vitro; 2014 Mar; 28(2):187-97. PubMed ID: 24055890
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of quercetin on the bioavailability of doxorubicin in rats: role of CYP3A4 and P-gp inhibition by quercetin.
    Choi JS; Piao YJ; Kang KW
    Arch Pharm Res; 2011 Apr; 34(4):607-13. PubMed ID: 21544726
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Time and dose dependent study of doxorubicin induced DU-145 cytotoxicity.
    Al-Ghamdi SS
    Drug Metab Lett; 2008 Jan; 2(1):47-50. PubMed ID: 19356070
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhanced cytotoxicity of monoclonal anticancer antibody 2C5-modified doxorubicin-loaded PEGylated liposomes against various tumor cell lines.
    Elbayoumi TA; Torchilin VP
    Eur J Pharm Sci; 2007 Nov; 32(3):159-68. PubMed ID: 17707615
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modulatory effects of heparin on cellular accumulation and cytotoxicity of doxorubicin in MRP1-overexpressing HL60/doxo cells.
    Angelini A; Ciofani G; Baccante G; Di Febbo C; Carmine DI; Cuccurullo F; Porreca E
    Anticancer Res; 2007; 27(1A):351-5. PubMed ID: 17352253
    [TBL] [Abstract][Full Text] [Related]  

  • 37. α-Tocopherol succinate improves encapsulation and anticancer activity of doxorubicin loaded in solid lipid nanoparticles.
    Oliveira MS; Mussi SV; Gomes DA; Yoshida MI; Frezard F; Carregal VM; Ferreira LAM
    Colloids Surf B Biointerfaces; 2016 Apr; 140():246-253. PubMed ID: 26764108
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs.
    Danesi R; Fogli S; Gennari A; Conte P; Del Tacca M
    Clin Pharmacokinet; 2002; 41(6):431-44. PubMed ID: 12074691
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel folated and non-folated pullulan bioconjugates for anticancer drug delivery.
    Scomparin A; Salmaso S; Bersani S; Satchi-Fainaro R; Caliceti P
    Eur J Pharm Sci; 2011 Apr; 42(5):547-58. PubMed ID: 21371555
    [TBL] [Abstract][Full Text] [Related]  

  • 40. P-glycoprotein induction and tumor cell-kill dynamics in response to differential doxorubicin dosing strategies: a theoretical pharmacodynamic model.
    Luu KT; Uchizono JA
    Pharm Res; 2005 May; 22(5):710-5. PubMed ID: 15906164
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.